Overview of Telma-CT

Property	Description
Active Ingredients	Telmisartan, Chlorthalidone
Form	Oral tablet
Pharmacological Class	Antihypertensive agents
General Purpose	Management of high blood pressure (hypertension)
Origin	Synthetic

The medication known commercially as Telma-CT is a fixed-dose combination drug for oral administration, firmly classified as an antihypertensive agent. This proprietary formulation, containing the synthetic active ingredients Telmisartan and Chlorthalidone, is designed for the management of high blood pressure (hypertension) in adults as part of a strategy for cardiovascular prevention. The medicine is supplied as a prescription-only oral tablet.

Defining the Fixed-Dose Combination Principle

This medicine integrates two distinct active ingredients into a single oral tablet, a clinical approach that is clinically recognized for achieving greater efficacy than single-agent treatments. As an antihypertensive agent, this dual formulation is specifically designed to target high pressure via multiple physiological actions, a method often found to be more robust for controlling chronic hypertension. Other widely recognized brands featuring this same combination therapy include Telvas-CT and Arbitel-CT.

Composition: Dual Active Ingredients and Their Classes

The composition is defined by the inclusion of two core chemical substances with complementary mechanisms. Telmisartan belongs to the Angiotensin II Receptor Blocker (ARB) class of medications, acting to promote vasodilation. The second ingredient, Chlorthalidone, is a thiazide-like diuretic, functioning primarily to increase the elimination of salt and water (diuresis) by the kidneys. Clinical evidence has consistently supported the use of thiazide-like diuretics as an established first-line therapy for hypertension, providing a strong pharmacological rationale for this combination.

General Purpose and Benefit of the Dual Action

The general purpose of utilizing this combination therapy is to deliver a superior and more consistent reduction of high blood pressure compared to the effects of either Telmisartan or Chlorthalidone if administered separately. This dual action maximizes the antihypertensive effect, which is the necessary benefit for reducing the long-term risk of adverse cardiovascular events in hypertensive patients. A typical, neutral use scenario involves managing patients whose blood pressure remains insufficiently controlled on a single antihypertensive agent.

What side effects are possible with Telma-CT?

Possible Side Effects and Safety Information

The safety profile of Telma-CT (Telmisartan/Chlorthalidone) is based on the known effects of its two active components, as documented in official regulatory labeling. This information describes officially reported adverse reactions and safety restrictions.

Common Adverse Reactions

Adverse reactions reported in clinical trials with an incidence of 1% or greater typically include:

Dizziness
Upper respiratory tract infection
Sinusitis
Diarrhea
Fatigue

System-Organ Classes and Associated Risks

Adverse effects are categorized by the body system affected, with key areas being:

Metabolism and Nutrition Disorders: Risks of electrolyte imbalance, including both hypokalemia (low potassium) and hyperkalemia (high potassium), as well as hyponatremia (low sodium).
Vascular Disorders: Hypotension (low blood pressure), especially upon standing.
Skin and Subcutaneous Tissue Disorders: Includes rash and the risk of angioedema (swelling of the face, lips, or throat).

Serious and Clinically Significant Adverse Reactions

Regulatory documents highlight several serious safety concerns:

Fetal Toxicity: Use during the second and third trimesters of pregnancy is strictly contraindicated due to the risk of injury and death to the developing fetus.
Acute Renal Failure: Worsening of kidney function, particularly in susceptible patients.
Angioedema: A potentially life-threatening hypersensitivity reaction associated with the Telmisartan component.
Ocular Toxicity: Rare risk of Acute Myopia and Secondary Angle-Closure Glaucoma associated with the Chlorthalidone component.

Population-Specific Restrictions

Telma-CT is contraindicated or not recommended for use in the following populations due to increased risk, as specified in regulatory documents:

Pregnancy (second and third trimesters)
Patients with Anuria (absence of urine production)
Patients with Severe Hepatic Impairment or Biliary Obstructive Disorders
Patients with known hypersensitivity to any sulfonamide-derived drug (like Chlorthalidone).

Note: Regular monitoring of serum electrolytes and renal function may be required during treatment to manage potential risks associated with the diuretic component.

Overdose and Emergency Response

Overdose and When to Seek Help

Any suspected ingestion of an excessive dose of Telmisartan/Chlorthalidone requires immediate medical attention. This regulatory requirement is due to the risk of severe, life-threatening manifestations documented in official prescribing information.

Documented Manifestations and Severe Risks

The clinical presentation of an overdose is an exaggeration of the drug's intended effects. The most likely sign of Telmisartan overdose is severe hypotension (extremely low blood pressure), which can manifest as dizziness, lethargy, or somnolence.

The Chlorthalidone component primarily causes hypovolemia, dehydration, and significant electrolyte imbalances, particularly hypokalemia (low potassium). Severe or uncontrolled overdose may lead to serious outcomes, including circulatory collapse (shock) and acute kidney injury. These complications are often more pronounced in patients with pre-existing volume depletion or impaired renal function.

Regulatory Actions and Management

Urgent Care Required: Patients must seek immediate medical attention for any signs of severe hypotension or compromised circulation.
Management Focus: Treatment is defined as symptomatic and supportive. Procedures focus on maintaining circulatory volume and correcting electrolyte and fluid imbalance. Close monitoring of blood pressure, serum electrolytes, and renal function is required during management.
Antidote Statement: Official labeling states that no specific antidote is known for this combination product.

Therapeutic Uses of Telma-CT

What Telma-CT Treats: Main Uses and Benefits

Telma-CT is commonly used to help manage essential hypertension (high blood pressure) across conditions where additional symptomatic support is needed to achieve and maintain target blood pressure goals. This combination is applied to help manage symptoms that create noticeable physiological strain. The relevant therapeutic uses include managing uncontrolled hypertension, contributing to easing the long-term cardiovascular burden, and providing supportive fluid management.

By maintaining stable and lower blood pressure over time, this therapeutic approach supports the patient by helping protect against future serious events like stroke and heart attack. This is relevant for easing the long-term burden associated with cardiovascular events.

“This medication is relevant for easing the long-term burden associated with cardiovascular events and contributes to maintaining a sense of functional stability.”

The medication is relevant for easing symptoms related to excess body fluid and salt retention. This action addresses symptom clusters that may become intense or disruptive and contributes to easing the overall symptom load. This supportive action contributes to improved comfort during symptomatic periods and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Relief for Fluid-Related Discomfort

Regulatory References

Rwanda FDA

Eligibility and Restrictions for Use

The official regulatory eligibility profile for Telma-CT, a fixed-dose combination of Telmisartan and Chlorthalidone, strictly defines which populations are permitted, restricted, or prohibited from using the medicine.

Eligibility Scope

Population Status	Eligibility Rule
Allowed (Standard Labeled)	Adults for the management of high blood pressure.
Contraindicated (Must Not Use)	Known hypersensitivity to Telmisartan, Chlorthalidone, or any sulphonamide-derived drugs.
	Patients with anuria, severe hepatic impairment, or severe renal impairment (creatinine clearance < 30 mL/min/1.73 m^2).
	Patients in the second and third trimesters of pregnancy or who are breastfeeding.
Not Recommended/Restricted	Children and adolescents under 18 years of age (safety/efficacy not established).
	Patients in the first trimester of pregnancy (discontinuation advised).

Condition-Specific Eligibility

Use is contraindicated when co-administered with Aliskiren-containing products in patients with Diabetes Mellitus or certain Renal Impairment statuses. Use requires caution and monitoring in patients with mild-to-moderate hepatic or renal impairment and those with volume or salt depletion, which must be corrected prior to treatment initiation.

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use the drug primarily through absolute contraindications related to hypersensitivity and severe organ dysfunction, particularly the liver and kidneys. Eligibility is further constrained by age, with a formal exclusion for children and specific prohibitions during pregnancy and lactation. All use outside of the approved adult population is officially restricted or not recommended.

What should I know about interactions with other medicines?

The interaction profile for Telma-CT, a fixed-dose combination of Telmisartan and Chlorthalidone, is documented based on pharmacodynamic effects and the potential to alter systemic drug exposure. Regulatory information defines specific constraints for co-administration.

Contraindicated and Restricted Combinations

The co-administration of Aliskiren is formally contraindicated when prescribed to patients diagnosed with diabetes mellitus. Furthermore, Telma-CT should not be combined with Potassium supplements or Potassium-containing salt substitutes, as this increases the documented risk of hyperkalemia (elevated serum potassium levels). A strict low-salt diet should also be avoided, as it may exacerbate documented electrolyte imbalances.

Pharmacodynamic and Exposure Effects

Combining Telma-CT with other agents that block the Renin-Angiotensin-Aldosterone System (RAS), such as ACE Inhibitors, is generally not recommended due to the heightened risk of severe hypotension and compromised renal function. The co-administration of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may cause a reduction in the drug's antihypertensive and diuretic efficacy and elevates the risk of renal deterioration, particularly in elderly or volume-depleted patients. Additionally, the regulatory label notes that co-administration with Lithium may result in a reversible increase in serum lithium concentrations, and Digoxin co-administration is reported to increase Telmisartan's systemic exposure. Alcohol (Ethanol) may exhibit additive effects in lowering blood pressure.

Mechanism of Action

Telma-CT operates through a dual-mechanism approach by combining the pharmacological actions of telmisartan and chlorthalidone.

Telmisartan functions as a selective, non-peptide antagonist at the Angiotensin II type 1 receptor (AT1). By occupying the AT1 receptor, primarily in vascular smooth muscle and the adrenal gland, telmisartan competitively blocks the binding and vasoconstrictive effects of the endogenous ligand, Angiotensin II. This antagonism inhibits the Angiotensin II-mediated intracellular signaling cascades, which typically include Gq protein coupling leading to IP3 and DAG production, resulting in reduced intracellular calcium and systemic smooth muscle contraction. Furthermore, AT1 blockade decreases Angiotensin II-stimulated aldosterone secretion from the adrenal cortex, modulating the downstream renal retention of sodium and water.

Chlorthalidone, a thiazide-like diuretic, acts primarily within the renal distal convoluted tubule. Its mechanism involves non-competitive inhibition of the apical Na^+/ Cl^- cotransporter (NCC or SLC12 A3). This molecular interaction decreases the reabsorption of luminal sodium and chloride ions into the tubular cells. The resultant increase in solute concentration within the filtrate enhances osmotic water excretion. The net effect of this renal pathway modulation is a reduction in plasma volume and extracellular fluid volume, leading to a decrease in cardiac output and, subsequently, systemic vascular fluid dynamics.

Dosage and Administration Information

Official Administration Guidelines for Telma-CT

This section outlines the instructions for the proper use of the Telmisartan and Chlorthalidone fixed-dose combination.

Administration Property	Official Instruction
Route of Administration	Oral route only.
Standard Dosing	Taken once daily. Doses are individualized, typically ranging from 40 mg/12.5 mg up to 80 mg/25 mg (Telmisartan/Chlorthalidone).
Timing in Relation to Meals	May be administered with or without food.
Preparation & Handling	Tablet must be swallowed whole with liquid. Due to moisture sensitivity, the tablet should not be removed from the sealed blister until immediately before administration.
Titration Schedule	Dose adjustment is generally assessed after 2 to 4 weeks of treatment to allow the maximal antihypertensive effect to be attained.
Population-Specific Rules	For patients with mild to moderate hepatic impairment, treatment should be initiated at the lower Telmisartan component dose (e.g., 40 mg/12.5 mg). No initial dose adjustment is explicitly required for elderly patients.

These official instructions establish a structured, continuous, once-daily oral regimen. The protocol defines a waiting period of several weeks before any dose increase, reflecting the time needed for the medicine to achieve its full effect. Adherence to the special handling instruction ensures the stability and effectiveness of the fixed-dose tablet.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Telma-CT

This overview presents the structure of the clinical research for the fixed-dose combination of Telmisartan and Chlorthalidone (Telma-CT). It focuses strictly on what types of studies have been conducted and what outcomes were monitored, without providing medical advice or claiming any performance benefits.

Evidence for Use in Blood Pressure Control

The research base focuses on studies that examined outcomes related to blood pressure and primarily involves Randomized Controlled Trials (RCTs) over short to intermediate time intervals. These studies were used in research exploring how blood pressure measurements change over time in adult patients, including those who had not achieved their blood pressure goals on a single antihypertensive medication prior to enrollment.

Studies explored outcomes related to physiological strain, specifically monitoring the change in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Trials described the measured changes in SBP and DBP over observation periods typically lasting 4 to 12 weeks. However, the generalizability of these findings is constrained because follow-up durations were limited, meaning the long-term monitoring of blood pressure measurements over periods longer than one year has not been fully established by combination-specific trials.

Evidence Landscape for Long-Term Cardiovascular Risk

Research has also examined long-term outcomes related to physical discomfort and systemic imbalance, which may be associated with high blood pressure. This research primarily relies on systematic reviews and meta-analyses that explored the evidence from trials of the individual drug classes (Telmisartan and Chlorthalidone).

The outcomes monitored in this broader research base include the incidence of major cardiovascular events, such as stroke and heart attack, and overall mortality endpoints. A key point is that the evidence for long-term health event changes is largely indirect. Outcome trials specific to this exact fixed-dose combination for the long-term reduction of cardiovascular events are limited, requiring the extrapolation of findings from the individual components.

Study Durations, Subgroups, and Research Gaps

Most efficacy research focused on short-term changes, typically lasting a few months, and monitored patient-reported outcomes describing their experience. Findings indicated that the measured blood pressure changes were observed to continue throughout these short observation periods.

Research examined outcomes in subgroups where co-existing conditions, such as type 2 diabetes, were present. However, the results apply only to the populations studied. The primary research limitation is the limited information for long-term outcomes that measure major health events and mortality for this specific fixed-dose combination, meaning the generalizability to all patients with hypertension is not fully established.

Key Studies & References

TELMITAB-80CT (Telmisartan 80mg and Chlorthalidone 12.5mg tablets) - Summary of Product Characteristics (SmPC)

Frequently Asked Questions (FAQ)

Common questions about Telma-CT (FAQ)

Q: What are the most common side effects people complain about with Telma-CT?

A: Official product information provides a list of adverse reactions and their frequency based on clinical trials. The list includes common effects such as dizziness, fatigue, upper respiratory tract infection, sinusitis, and diarrhea. However, regulatory documents do not provide ranking based on how often patients 'complain' or report subjective severity beyond numerical incidence rates.

Q: Can Telma-CT cause leg swelling or fluid retention?

A: While the chlorthalidone component of Telma-CT is designed to help reduce excess fluid, official post-marketing reports for the telmisartan component have noted a low incidence of peripheral edema, which is swelling of the limbs. Any new or concerning swelling should be reported to the prescribing healthcare professional.

Q: Does Telma-CT interact with common pain relievers like ibuprofen?

A: Official drug warnings address the co-administration of Telma-CT with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen. This combination may reduce the blood pressure-lowering effect of Telma-CT and carries a heightened risk of worsening kidney function, particularly in certain susceptible patients.

Q: Do older people react differently to Telma-CT than younger adults?

A: Regulatory documents indicate that no initial dose adjustment is explicitly required for elderly patients based on age alone. However, older patients may be more susceptible to certain side effects or interactions, such as the increased risk of kidney issues when combining Telma-CT with NSAIDs. As with any medication, the treatment plan requires continuous assessment by a healthcare professional.

Q: Can Telma-CT affect blood sugar levels, especially for people with diabetes?

A: The chlorthalidone component of Telma-CT is associated with risks of metabolic changes, including an elevation of blood sugar, known as hyperglycemia. Patients with diabetes may require adjustment to their current blood sugar-lowering medications. Any changes to a treatment plan should be made by a healthcare professional.

Q: Are there any long-term studies on the safety of taking Telma-CT for many years?

A: Clinical trials conducted specifically on the fixed-dose combination of Telmisartan and Chlorthalidone often focus on short-term efficacy, typically lasting a few weeks. Therefore, evidence for the long-term reduction of major cardiovascular events relies primarily on extrapolating findings from studies of the individual components.

Q: What happens if I forget to take my Telma-CT dose one day?

A: Official instructions advise that a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and a double dose should not be taken. It is important to return to the regular dosing schedule.

Q: Why does Telma-CT combine two different types of blood pressure drugs?

A: The combination is a clinically recognized strategy designed to achieve greater blood pressure reduction than either component used alone. This is achieved because the two drugs work on complementary mechanisms: Telmisartan relaxes blood vessels, and Chlorthalidone helps the body excrete excess salt and water.

Q: Is there any risk of rebound hypertension if I stop taking Telma-CT suddenly?

A: Clinical studies on the Telmisartan component show that blood pressure tends to return gradually to pretreatment levels over a period of several days to a week after treatment is stopped. While a sharp rebound is not typically expected, for any change in treatment, including discontinuation, consultation with the prescribing healthcare professional is necessary.

Q: Can Telma-CT cause fatigue or make me feel tired?

A: Fatigue is listed among the adverse reactions commonly reported in clinical trials for the medication. Any unusual or persistent tiredness should be discussed with a healthcare provider.

Q: Can Telma-CT impact cholesterol levels?

A: The chlorthalidone component, which is a diuretic, is noted in the official product labeling as having the potential to cause elevations in serum lipids, such as cholesterol. This is classified as a metabolic effect that may require monitoring during treatment.

Q: Is Telma-CT considered a diuretic?

A: Telma-CT is classified as a fixed-dose combination and an overall antihypertensive agent. While it is not strictly a diuretic, one of its two active ingredients, Chlorthalidone, is a thiazide-like diuretic that helps remove excess salt and water from the body.

Q: How long does the effect of one Telma-CT pill last?

A: The once-daily dosing regimen is supported by the pharmacokinetic properties of the active ingredients. The Telmisartan component, for example, has an elimination half-life of approximately 24 hours, which contributes to a continuous effect on blood pressure over a full day.

Q: Can Telma-CT affect sleep or cause insomnia?

A: Official adverse reaction reports for the Telmisartan component have included insomnia (difficulty sleeping) as a reported adverse experience. Any change in sleep patterns after starting the medication is a subject for discussion with a healthcare professional.

Q: Is Telma-CT safe for people with a history of gout?

A: The chlorthalidone component of the medication may cause an increase in serum uric acid levels. The potential for increased uric acid is a factor to be considered by the prescribing professional for individuals with a history of gout.

Q: Why do some forums mention Telma-CT causing muscle cramps?

A: Regulatory warnings indicate that the chlorthalidone component can lead to electrolyte disturbances, such as low potassium (hypokalemia) or low sodium (hyponatremia). These types of mineral imbalances are known to be associated with side effects like muscle cramps and weakness.

Q: What is the average time it takes to see the maximum blood pressure lowering effect from Telma-CT?

A: Official regulatory documents indicate that the maximal blood pressure reduction from Telma-CT is generally reached after approximately four weeks of consistent treatment. This waiting period is why dose adjustment is typically not assessed until 2 to 4 weeks after starting the medication.

Q: Can Telma-CT cause dry mouth?

A: Dry mouth has been reported as an adverse experience for the Telmisartan component in official drug labeling. Additionally, dry mouth can be a clinical sign of the fluid and electrolyte imbalances that are a potential risk with the chlorthalidone component.

Q: Is Telma-CT used as a first-line treatment for high blood pressure?

A: The official indication is for the treatment of essential hypertension in adult patients whose blood pressure is not adequately controlled with monotherapy (a single agent). Therefore, it is typically used when initial treatment with one medication has been insufficient.

Q: Can taking Telma-CT affect mineral balance in the body, like potassium?

A: Yes, one of the key safety concerns highlighted in the official warnings is the risk of electrolyte imbalance due to the chlorthalidone component. This can specifically lead to either low potassium (hypokalemia) or high potassium (hyperkalemia), both of which require monitoring.

Q: Are there any research papers discussing the combination of Telmisartan and Chlorthalidone?

A: The efficacy of this combination is supported by clinical data referenced in regulatory documents. This includes summaries of Randomized Controlled Trials (RCTs) that studied the combination's effect on lowering blood pressure in adults.

Q: Can Telma-CT cause changes in mood or make you feel down?

A: The Telmisartan component's adverse reaction profile includes reports of psychiatric symptoms such as anxiety and depression. Furthermore, severe electrolyte imbalances caused by the diuretic component can sometimes manifest as changes in mood or mental state.

How should Telma-CT be stored and disposed of?

How to Store and Dispose of Telma-CT (Telmisartan/Chlorthalidone)

Telmisartan and Chlorthalidone tablets must be stored according to official regulatory labeling to ensure stability and potency.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Protection	Mandatory protection from moisture, as the product is hygroscopic.
Container Rule	Tablets should not be removed from the original packaging until immediately prior to use; the container must be tightly closed.
Child Safety	Must be stored out of the sight and reach of children.

Disposal

Unused or expired Telmisartan/Chlorthalidone tablets must be discarded according to local regulations. Official guidance recommends using a drug take-back program or an authorized collection site where available for proper disposal.

Telma-CT